Skip to main content

Table 1 Patient characteristics

From: A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation

Characteristics

Training cohort (n = 335)

Validation cohort (n = 135)

P value

Median age at allo-HSCT, years (range)

28 (1–66)

31 (1–64)

0.596

Gender, n (%)

0.635

 Male

198 (59.1)

83 (61.5)

 

 Female

137 (40.9)

52 (38.5)

 

Underlying disease, n (%)

0.704

 Acute myeloid leukemia

187 (55.8)

78 (57.8)

 

 Acute lymphoblastic leukemia

143 (42.77)

55 (40.7)

 

 Mixed-phenotype acute leukemia

5 (1.55)

2 (1.5)

 

Disease status before allo-HSCT, n (%)

0.535

 CR1

321 (95.8)

131 (97.0)

 

 > CR1

14 (4.2)

4 (3.0)

 

Disease risk index before allo-HSCT, n (%)

0.714

 Low and intermediate risk

268 (80.0)

110 (81.5)

 

 High and very high risk

67 (20.0)

25 (18.5)

 

Donor/recipient relation, n (%)

0.379

 Mother donor

26 (7.8)

12 (8.9)

 

 Collateral donor

12 (3.6)

0 (0.0)

 

 Others

297 (88.7)

123 (91.1)

 

Donor/recipient gender matched, n (%)

0.258

 Female donor/male recipient combination

57 (17.0)

29 (21.5)

 

 Others

278 (83.0)

106 (78.5)

 

HCT-CI scores before allo-HSCT, n (%)

0.121

 0 (Low-risk)

237 (70.7)

105 (77.8)

 

 1–2 (Intermediate-risk)

74 (22.1)

23 (17.0)

 

 ≥ 3 (High-risk)

24 (7.2)

7 (5.2)

 

Median donor age at allo-HSCT, years (range)

40 (9–70)

36 (10–63)

0.094

Cytomegalovirus serostatus before HSCT, n (%)

0.501

 Donor +/recipient +

312 (93.1)

128 (94.8)

 

 Donor +/recipient −

11 (3.3)

3 (2.2)

 

 Donor −/recipient + 

10 (3.0)

4 (3.0)

 

 Donor −/recipient −

2 (0.6)

0 (0.0)

 

Number of HLA-A, HLA-B, HLA-DR mismatches, n (%)

0.914

 1 Locu

8 (2.4)

3 (2.2)

 

 ≥ 2 Loci

327 (97.6)

132 (97.8)

 

Blood group compatibility, n (%)

0.719

 Matched

175 (52.2)

73 (54.1)

 

 Mismatched

160 (47.8)

62 (45.9)

 

Conditioning regimen, n (%)

0.350

 Chemotherapy-based regimen

325 (97.0)

133 (98.5)

 

 TBI-based regimen

10 (3.0)

2 (1.5)

 

Cell type, median count (range)

 MNC counts (× 108/kg)

9.2 (4.4–27.3)

9.3 (4.2–27.5)

0.218

 CD34+ cell counts (× 106/kg)

3.8 (0.7–25.33)

3.9 (1.1–29.4)

0.572

 CD3+ cell counts (× 106 kg)

340.9 (116.2–874.2)

352.0 (170.4–1172.2)

0.617

 CD4+ cell counts (× 106/kg)

182.5 (68.3–600.1)

184.7 (75.2–492.7)

0.688

 CD8+ cell counts (× 106/kg)

126.7 (29.6–347.9)

128.0 (46.1–1511.2)

0.559

 CD14+ cell counts (× 106/kg)

211.3 (73.3–1065.0)

215.6 (95.8–716.9)

0.373

 CD8+/CD3+ cells ratio

0.4 (0.2–0.7)

0.4 (0.1–1.3)

0.817

 CD4+/CD8+ cells ratio

1.5 (0.4–4.7)

1.5 (0.3–3.0)

0.672

 CD4+/CD3+ cells ratio

0.6 (0.2–0.8)

0.5 (0.1–0.7)

0.627

 CD3+/CD14+ cells ratio

1.6 (0.6–4.4)

1.5 (0.6–3.7)

0.601

Median follow-up of survivors, days (range)

203 (62–490)

192 (52–509)

0.134

  1. allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete remission; HLA, human leukocyte antigen; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MNC, mononuclear cells; TBI, total body irradiation